Insilico has signed a multi-year US$888m oncology deal with Servier to use AI in discovering and developing cancer therapies.
The AI-driven drug discovery company will use its Pharma.AI platform to identify and advance potential drug candidates, while Servier will lead clinical validation, regulatory interactions and worldwide commercialisation.
Under the agreement, Insilico will be eligible to receive up to US$32m in upfront and near-term research and development payments, with Servier sharing R&D costs.
Christophe Thurieau, executive director of research at Servier, said: “This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform.”
Alex Zhavoronkov, founder and chief executive of Insilico Medicine, said: “I am excited to see the collaboration—it is yet another strong acknowledgement of our AI capabilities and R&D expertise.
“As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.”
Insilico said it has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline of 12 to 18 months per programme, compared with an industry average of 4.5 years for early-stage drug discovery.
The company listed on the Hong Kong Stock Exchange on 30 December 2025.
